simendan has been researched along with Left Ventricular Dysfunction in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 39 (46.43) | 29.6817 |
| 2010's | 34 (40.48) | 24.3611 |
| 2020's | 11 (13.10) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, JH; Caruba, T; Charles-Nelson, A; Chatellier, G; Cholley, B; Heringlake, M; Mehta, RH; Sabatier, B; Toller, W; Yavchitz, A | 1 |
| Alexander, JH; Argenziano, M; de Varennes, B; Duncan, AI; Fremes, S; Goodman, SG; Kochar, A; Lopes, RD; Mazer, DC; Mehta, RH; van Diepen, S; Westerhout, CM; Whitlock, R; Zheng, Y | 1 |
| Dresbach, T; Geipel, A; Holcher, S; Kipfmueller, F; Leyens, J; Mueller, A; Schroeder, L; Strizek, B | 1 |
| Biais, M; Carrie, C; Cottenceau, V; Gariel, F; Petit, L; Poutier, B; Sauvage, N | 1 |
| Agostoni, P; Cosentino, N; Fracassi, F; Marenzi, G; Niccoli, G; Rebuzzi, A | 1 |
| Caliskan, K; Yalcin, YC | 1 |
| Allam, M; Dawou, O; Eldegwy, M; Elshihy, E; Omar, A; Rouchdy, A; Soliman, SAH | 1 |
| Akchurin, RS; Dzybinskaya, EV; Gazizova, VP; Gramovich, VV; Shiryaev, AA; Stukalova, OV; Vlasova, EE | 1 |
| Alexander, JH; Alhanti, B; Fremes, S; Goodman, SG; Heringlake, M; Jawitz, OK; Lopes, RD; Mehta, RH; Meyer, SR; Raman, V; Stafford-Smith, M; Stebbins, AS; van Diepen, S; Whitlock, R | 1 |
| Ahlawat, V; Kumar, D; Kundu, A; Prakash, A; Yadav, A; Yadava, OP | 1 |
| Cui, DY; Hu, S; Hu, Y; Kuang, X; Liu, ZZ; Long, YX; Wang, CP | 1 |
| Alexander, JH; Anstrom, KJ; Argenziano, M; Bozinovski, J; Duncan, A; Fremes, S; Goodman, SG; Harrington, RA; Harrison, RW; Hay, D; Heringlake, M; Jankowich, R; Kalavrouziotis, D; Leimberger, JD; Levy, JH; Luber, J; Marcel, R; Mehta, RH; Meza, J; Murphy, E; Nagpal, D; Park, S; Soltesz, EG; Toller, W; van Diepen, S; Wang, A | 1 |
| Fernández-Ruiz, I | 1 |
| Adzhigaliev, RR; Belov, SI; Berezhnoy, SA; Panov, OS; Pasyuga, VV; Tarasov, DG; Yavorovsky, AG; Yusupova, ES | 1 |
| Chen, P; Hu, X; Huang, J; Peng, X; Tang, L; Xing, Z | 1 |
| Cheng, B; Gong, Y; He, X; Wang, B | 1 |
| Chan, XL; Ng, KT; Tan, W; Wang, CY | 1 |
| Bertini, P; Borrelli, N; Ferraiuolo, G; Guarracino, F; Penco, M; Poli, M; Romano, S; Trambaiolo, P | 1 |
| Alexander, JH; Anstrom, KJ; Argenziano, M; Cowper, PA; Duncan, AE; Fremes, S; Goodman, SG; Heringlake, M; Jankowich, R; Knight, JD; Leimberger, JD; Levy, JH; Lopes, RD; Luber, J; Mark, DB; Mehta, RH; Nagpal, AD; Teoh, K; Toller, W; van Diepen, S | 1 |
| Caliskan, K; Delnoij, TS; Donker, DW; Maessen, JG; Weerwind, PW; Wetzels, AE | 1 |
| Elisha, N; Paret, G; Rubinsthein, M; Salem, I | 1 |
| Alexander, JH; Harrington, RA; Harrison, RW; Hasselblad, V; Levin, R; Mehta, RH | 1 |
| Andersson, KB; Christensen, G; Golz, S; Hillestad, V; Knorr, A; Kramer, F | 1 |
| Cruz, J; Escalona, JJ; Florez, A; Galan, M; Iglesias, P; Melero, JM; Orriach Guerrero, JL; Ramirez Fernandez, A; Ramirez, M; Rodriguez, MJ; Rubio, M | 1 |
| Beutlhauser, T; Erb, J; Feldheiser, A; Grubitzsch, H; Schuster, B; Spies, C; Treskatsch, S | 1 |
| Akturk, IF; Birant, A; Erturk, M; Karakurt, H; Kurtar Mansıroglu, A; Oner, E; Somuncu, MU; Uzun, F; Yalcin, AA; Yildirim, A | 1 |
| Bishnoi, A; Gandhi, H; Gandhi, S; Garg, P; Malhotra, A; Sharma, P | 1 |
| Cismowski, MJ; de Tombe, P; Guggilam, A; Lucchesi, PA; Sadayappan, S; Trask, AJ; West, TA; Wilson, K; Zhang, X | 1 |
| Abacilar, AF; Akpinar, MB; Alayunt, EA; Ates, M; Gul, I; Okur, FF; Sahin, V; Tavli, T; Uc, H; Uyar, IS | 1 |
| Balzer, F; Braun, JP; Erb, JM; Geyer, T; Grubitzsch, H; Kastrup, M; Sander, M; Spies, CD; Treskatsch, S; Wernecke, KD | 1 |
| Acea, AB; Ferrer Hita, JJ; García-González, MJ; Jiménez-Sosa, A; Jorge-Pérez, P; Lacalzada Almeida, JB | 1 |
| Altarabsheh, SE; Avery, EG; Cho, YH; Deo, SV; Hang, D; Lim, JY; Markowitz, AH; McGraw, M; Park, SJ; Rababa'h, A | 1 |
| Avram, R; Desplantie, O; Ducharme, A; Jolicoeur, EM; Marquis-Gravel, G; Tremblay-Gravel, M | 1 |
| Andrea, R; Brugaletta, S; Farrero, M; Fita, G; Freixa, X; Hernández, M; Jiménez, G; Martín-Yuste, V; Masotti, M; Regueiro, A; Sabaté, M; Sitges, M; Tatjer, I | 1 |
| Axelsson, B; Gupta, A; Häggmark, S; Haney, M; Johansson, G; Svenmarker, S; Tydén, H; Wouters, P | 1 |
| Arya, VK; Dutta, V; Kumar, B; Mishra, A; Mishra, AK | 1 |
| Anastasiadis, K; Antonitsis, P; Argiriadou, H; Asteriou, C; Grosomanidis, V; Kleontas, A; Tossios, P; Vranis, K | 1 |
| Almeida, C; Aucouturier, P; Caruba, T; Chatellier, G; Cholley, B; Djadi-Prat, J; Freitas, N; Gomes, N; Hoffart-Jourdain, C; Hourton, D; Menasché, P; Rousseau, D; Sabatier, B; Souag, A; Tibi, A; Yjjou, M | 1 |
| Arnold, A; Böning, A; Görlach, G; Grieshaber, P; Lipp, S; Niemann, B; Roth, P; Wilhelm, J; Wollbrück, M | 1 |
| Alexander, JH; Anstrom, KJ; Bokesch, P; Fremes, S; Goodman, SG; Harrington, RA; Harrison, RW; Hay, D; Heringlake, M; Jankowich, R; Leimberger, JD; Levy, JH; Luber, J; Mehta, RH; Meza, J; Parrotta, J; Swartz, M; Toller, W; Tourt-Uhlig, S; Van Diepen, S | 1 |
| Greif, M; Reithmann, C; Weis, M; Zwermann, L | 1 |
| Mebazaa, A; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P | 1 |
| Eriksson, HI; Heikkinen, LO; Jalonen, JR; Kivikko, M; Kuitunen, AH; Kuttila, KT; Laine, M; Leino, KA; Peräkylä, TK; Salmenperä, MT; Sarapohja, T; Suojaranta-Ylinen, RT; Valtonen, M | 1 |
| Beiras-Fernandez, A; Kaczmarek, I; Kur, F; Reichart, B; Schmoeckel, M; Sodian, R; Weis, F; Weis, M | 1 |
| Adanir, T; Aksun, M; Aran, G; Gürbüz, A; Karahan, N; Ozgürbüz, U; Oztürk, T; Sencan, A; Yetkin, U | 1 |
| Kirkeby-Garstad, I; Kolseth, SM; Nordhaug, DO; Sellevold, O; Stenseth, R; Wahba, A | 1 |
| Abroug, F; Dachraoui, F; Dimassi, S; Mebazaa, A; Ouanes, I; Ouanes-Besbes, L | 1 |
| Apostolakis, S; Lazaridis, K; Spandidos, DA; Tzoras, S; Zaravinos, A | 1 |
| Brunetti, ND; Correale, M; D'Arienzo, G; De Gennaro, L; Di Biase, M; Dioguardi, E; Ieva, R; Pellegrino, PL; Ziccardi, L | 1 |
| Cheng, CP; Cheng, HJ; Little, WC; Masutani, S; Tachibana, H | 1 |
| Favilli, R; Focardi, M; Guarino, E; Lunghetti, S; Maffei, S; Mondillo, S; Palmerini, E; Urselli, R | 1 |
| Coats, AJ | 1 |
| Andrejevs, N; Golikov, AP; Kobalava, ZD; Laine, T; Lazebnik, LB; Lehtonen, LA; Lie, KI; Moiseyev, VS; Nieminen, MS; Põder, P; Ruda, MY | 1 |
| Borghi, C; Greenberg, B; Perrone, S | 1 |
| Follath, F | 1 |
| Anifantakis, A; Athanassopoulos, G; Chatzigeorgiou, G; Cokkinos, DV; Iakovis, P; Karatasakis, G; Koutsogiannis, N; Manginas, A; Maounis, T; Papadakis, M; Spargias, KS | 1 |
| Cavana, M; Fraticelli, A; Mebazaa, A; Pignataro, C | 1 |
| Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
| Chatterjee, K; Foster, E; Gerber, IL; Jordan, MV; Kostal, M; McKeown, B; Michaels, AD; Vakharia, KT | 1 |
| Domínguez-Rodríguez, A; Ferrer-Hita, JJ; García-González, MJ | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, G; Kremastinos, DT; Lekakis, J; Panou, F; Paraskevaidis, I; Parissis, JT; Venetsanou, K | 1 |
| Harjola, VP; Siirilä-Waris, K; Suojaranta-Ylinen, R | 1 |
| Benedetti, G; Bucciarelli-Ducci, C; Celotto, A; De Luca, L; Di Roma, A; Fedele, F; Genuini, I; Proietti, P; Sardella, G | 1 |
| Battagliese, A; Benedetti, G; De Luca, L; Di Roma, A; Fedele, F; Proietti, P; Sardella, G | 1 |
| Flaim, BD; MacIsaac, AI; Prior, DL; Yii, MY | 1 |
| Hoefer, D; Hoermann, C; Jonetzko, P; Laufer, G; Poelzl, G | 1 |
| Kivikko, M; Kupari, M; Laine, M; Lilleberg, J; Palkama, T; Pohjanjousi, P | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, G; Iliodromitis, E; Kremastinos, DT; Panou, F; Paraskevaidis, I; Parissis, JT | 1 |
| Bistola, V; Farmakis, D; Filippatos, G; Kourea, K; Kremastinos, D; Nikolaou, M; Panou, F; Paraskevaidis, I; Parissis, JT | 1 |
| González-Chon, O; Guevara, M; Márquez, MF; Rivera, J; Romero, KA; Uruchurtu, E | 1 |
| Flevari, P; Kourea, K; Kremastinos, DT; Leftheriotis, D; Panou, F; Parissis, JT | 1 |
| Lechner, E; Mair, R; Moosbauer, W; Pinter, M; Tulzer, G | 1 |
| Benezet-Mazuecos, J; de la Hera, J | 1 |
| Andreou, C; Colucci, WS; Conrad, CH; Givertz, MM | 1 |
| Pagel, PS | 1 |
| Auriti, A; Cianfrocca, C; Guido, V; Li, X; Mercuro, G; Pasceri, V; Pelliccia, F; Richichi, G; Santini, M | 1 |
| Abreu-González, P; Domínguez-Rodríguez, A; García-González, MJ; Samimi-Fard, S | 1 |
| Adreanides, E; Athanasopoulos, G; Cokkinos, DV; Dritsas, A; Giamouzis, G; Mavrogeni, S; Panagiotakos, D; Papadopoulou, E; Spargias, K; Thomopoulou, S; Vassiliadis, I | 1 |
| Guarracino, F; Morelli, A; Tritapepe, L | 1 |
| Baldassarri, R; Cariello, C; Danella, A; Doroni, L; Guarracino, F; Lapolla, F; Stefani, M; Vullo, C | 1 |
| Birhan, M; Yilmaz, MB | 1 |
| Jirmar, R; Kolesar, M; Nejedly, M; Vanek, T | 1 |
| Auriti, A; Cianfrocca, C; Guido, V; Mercuro, G; Pasceri, V; Pelliccia, F; Santini, M | 1 |
| Cleland, JG; McGowan, J | 1 |
14 review(s) available for simendan and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Prophylactic levosimendan in patients with low ejection fraction undergoing coronary artery bypass grafting: A pooled analysis of two multicentre randomised controlled trials.
Topics: Coronary Artery Bypass; Humans; Multicenter Studies as Topic; Postoperative Complications; Randomized Controlled Trials as Topic; Simendan; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction.
Topics: Animals; Cardiovascular Agents; Humans; Recovery of Function; Simendan; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials.
Topics: Cardiotonic Agents; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Randomized Controlled Trials as Topic; Simendan; Ventricular Dysfunction, Left | 2021 |
Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysis and trial sequential analysis of randomized trials.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Humans; Randomized Controlled Trials as Topic; Simendan; Ventricular Dysfunction, Left | 2018 |
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery: An Update Meta-Analysis and Trial Sequential Analysis.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Humans; Hydrazones; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Simendan; Ventricular Dysfunction, Left | 2018 |
Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Humans; Postoperative Complications; Preoperative Care; Simendan; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis.
Topics: Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Data Interpretation, Statistical; Hospital Mortality; Humans; Hydrazones; Perioperative Care; Postoperative Complications; Publication Bias; Pyridazines; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Simendan; Stroke Volume; Survival; Ventricular Dysfunction, Left | 2013 |
Preoperative levosimendan. A new way for organoprotection.
Topics: Animals; Cardiac Surgical Procedures; Humans; Hydrazones; Postoperative Complications; Preoperative Care; Pyridazines; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left | 2014 |
Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis.
Topics: Acute Kidney Injury; Adult; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Databases, Bibliographic; Humans; Hydrazones; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Ventricular Dysfunction, Left | 2015 |
The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies.
Topics: Bromocriptine; Cardiomyopathies; Echocardiography; Female; Humans; Hydrazones; Pentoxifylline; Pregnancy; Pregnancy Complications, Cardiovascular; Prospective Studies; Puerperal Disorders; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Ventricular Dysfunction, Left | 2015 |
Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?
Topics: Calcium Channel Blockers; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; United States; Vasodilator Agents; Ventricular Dysfunction, Left | 2003 |
The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
Topics: Adrenergic beta-Antagonists; Anesthesia; Calcium Channels, L-Type; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Intensive Care Units; Myocardial Contraction; Pyridazines; Shock, Cardiogenic; Simendan; Systole; Ventricular Dysfunction, Left | 2003 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
Levosimendan: a new era for inodilator therapy for heart failure?
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2002 |
34 trial(s) available for simendan and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Predictors and associated clinical outcomes of low cardiac output syndrome following cardiac surgery: insights from the LEVO-CTS trial.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Humans; Hydrazones; Postoperative Complications; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2022 |
Comparison of Levosimendan Versus IABP in Patients with Poor Left Ventricular Function Undergoing Coronary Artery Bypass Graft Surgery.
Topics: Cardiotonic Agents; Coronary Artery Bypass; Critical Care; Female; Hemodynamics; Humans; Infusions, Intravenous; Intra-Aortic Balloon Pumping; Length of Stay; Male; Middle Aged; Postoperative Complications; Prospective Studies; Risk Factors; Simendan; Ventricular Dysfunction, Left | 2020 |
Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.
Topics: Acute Kidney Injury; Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Odds Ratio; Placebos; Postoperative Complications; Regression Analysis; Risk Factors; Simendan; Stroke Volume; Ventricular Dysfunction, Left | 2021 |
Pre-bypass levosimendan in ventricular dysfunction-effect on right ventricle.
Topics: Cardiotonic Agents; Heart Ventricles; Humans; Hydrazones; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
Topics: Aged; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Double-Blind Method; Female; Heart-Assist Devices; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Mortality; Myocardial Infarction; Perioperative Period; Postoperative Complications; Pyridazines; Renal Replacement Therapy; Simendan; Stroke Volume; Treatment Failure; Ventricular Dysfunction, Left | 2017 |
[A COMPARISON OF TWO APPROACHES FOR INTRAOPERATIVE LEVOSIMENDAN ADMINISTRATION IN CARDIAC SURGICAL PATIENTS WITH SEVERE LEFT VENTRICLE DYSFUNCTION.]
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Injections, Intravenous; Intraoperative Care; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Troponin T; Ventricular Dysfunction, Left | 2016 |
Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hospital Costs; Humans; Male; Middle Aged; Postoperative Complications; Risk Assessment; Risk Factors; Simendan; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiomyopathies; Cardiotonic Agents; Coronary Artery Bypass; Double-Blind Method; Enoximone; Female; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2014 |
Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Pyridazines; Recovery of Function; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Turkey; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Preoperative levosimendan in ischemic mitral valve repair.
Topics: Adult; Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Heart Valve Prosthesis Implantation; Hemodynamics; Humans; Hydrazones; India; Intensive Care Units; Length of Stay; Male; Middle Aged; Mitral Valve Annuloplasty; Mitral Valve Insufficiency; Postoperative Complications; Preoperative Care; Prospective Studies; Pyridazines; Respiration, Artificial; Simendan; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Evaluation of myocardial contractility determination with tissue tracking echocardiography after levosimendan infusion in patients with poor left ventricular function and hemodynamics.
Topics: Cardiotonic Agents; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Echocardiography; Elasticity Imaging Techniques; Female; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Reproducibility of Results; Sensitivity and Specificity; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Cardiovascular Agents; Critical Illness; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Recovery of Function; Severity of Illness Index; Simendan; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Comparative Effect of Levosimendan and Milrinone in Cardiac Surgery Patients With Pulmonary Hypertension and Left Ventricular Dysfunction.
Topics: Adult; Aortic Valve; Arterial Pressure; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Hypertension, Pulmonary; Male; Middle Aged; Milrinone; Mitral Valve; Norepinephrine; Postoperative Care; Prospective Studies; Pulmonary Artery; Pyridazines; Simendan; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Left | 2016 |
Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study.
Topics: Cardiac Output, Low; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Finland; Follow-Up Studies; Humans; Hydrazones; Incidence; Infusions, Intravenous; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Survival Rate; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (≤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study).
Topics: Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass; Double-Blind Method; Heart-Assist Devices; Humans; Hydrazones; Perioperative Period; Pyridazines; Renal Replacement Therapy; Research Design; Simendan; Stroke Volume; Ventricular Dysfunction, Left | 2016 |
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requ
Topics: Administration, Intravenous; Adult; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function.
Topics: Aged; Analysis of Variance; Cardiopulmonary Bypass; Confidence Intervals; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Double-Blind Method; Education, Medical, Continuing; Female; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Monitoring, Intraoperative; Postoperative Complications; Preoperative Care; Prospective Studies; Pyridazines; Reference Values; Risk Assessment; Severity of Illness Index; Simendan; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Biomarkers; Cardiomyopathies; DNA; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2011 |
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Topics: Acute Disease; Aged; Analysis of Variance; Cardiotonic Agents; Double-Blind Method; Drug Evaluation; Endpoint Determination; Female; Heart Failure; Humans; Hydrazones; Hypotension; Male; Myocardial Infarction; Prospective Studies; Pyridazines; Risk Factors; Safety; Simendan; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Topics: Adrenergic beta-Agonists; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Death, Sudden, Cardiac; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Morbidity; Myocardial Contraction; Pulmonary Wedge Pressure; Pyridazines; Risk Factors; Severity of Illness Index; Shock, Cardiogenic; Simendan; Stroke Volume; Survival Analysis; Time; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2003 |
Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.
Topics: Adult; Aged; Aged, 80 and over; Coronary Circulation; Coronary Vessels; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardium; Oxygen Consumption; Pyridazines; Regional Blood Flow; Simendan; Vascular Resistance; Vasodilation; Vasomotor System; Ventricular Dysfunction, Left | 2005 |
Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Levosimendan in cardiac surgery.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Disease; Epinephrine; Female; Follow-Up Studies; Hemodynamics; Humans; Hydrazones; Male; Milrinone; Norepinephrine; Postoperative Care; Preoperative Care; Pyridazines; Risk Factors; Simendan; Time Factors; Vasoconstrictor Agents; Vasodilator Agents; Vasopressins; Ventricular Dysfunction, Left | 2005 |
Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction.
Topics: Angioplasty, Balloon, Coronary; Blood Flow Velocity; Coronary Circulation; Female; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2005 |
Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study.
Topics: Angioplasty, Balloon; Cardiotonic Agents; Echocardiography, Doppler; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Prognosis; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebos; Pulmonary Circulation; Pyridazines; Simendan; Systole; Time Factors; Ventricular Dysfunction, Left | 2007 |
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Cytokines; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Immunity, Cellular; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Treatment Outcome; Troponin T; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Effects of levosimendan on right ventricular function in patients with advanced heart failure.
Topics: Blood Pressure; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Interleukin-10; Interleukin-6; Male; Middle Aged; Natriuretic Peptides; Pulmonary Artery; Pyridazines; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right | 2006 |
Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
Topics: Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Circulation; Dose-Response Relationship, Drug; Heart; Heart Function Tests; Heart Rate; Humans; Hydrazones; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Contraction; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2007 |
Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography.
Topics: Cardiotonic Agents; Dobutamine; Echocardiography; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2007 |
Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyridazines; Shock, Cardiogenic; Simendan; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Output, Low; Cardiotonic Agents; Drug Administration Schedule; Echocardiography; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Hydrazones; Middle Aged; Mitral Valve Insufficiency; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume; Surveys and Questionnaires; Systole; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Strain rate analysis and levosimendan improve detection of myocardial viability by dobutamine echocardiography in patients with post-infarction left ventricular dysfunction: a pilot study.
Topics: Aged; Dobutamine; Drug Synergism; Echocardiography; Elasticity Imaging Techniques; Female; Humans; Hydrazones; Image Enhancement; Male; Myocardial Infarction; Pyridazines; Reproducibility of Results; Sensitivity and Specificity; Simendan; Ventricular Dysfunction, Left | 2008 |
36 other study(ies) available for simendan and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Evaluation of levosimendan as treatment option in a large case-series of preterm infants with cardiac dysfunction and pulmonary hypertension.
Topics: Adult; Calcium; Cardiac Output, Low; Cardiotonic Agents; Child; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Infant, Premature; Lactates; Simendan; Ventricular Dysfunction, Left | 2023 |
May levosimendan be safe and effective in refractory vasospasm despite adequate treatment with repeated angiography and milrinone infusion after subarachnoid haemorrhage?
Topics: Aneurysm, Ruptured; Cardiotonic Agents; Cerebral Angiography; Cerebrospinal Fluid Leak; Computed Tomography Angiography; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Embolization, Therapeutic; Humans; Infusions, Intravenous; Intracranial Aneurysm; Intracranial Pressure; Magnesium Sulfate; Male; Middle Aged; Milrinone; Nimodipine; Simendan; Subarachnoid Hemorrhage; Vasospasm, Intracranial; Ventricular Dysfunction, Left | 2019 |
Intermittent levosimendan treatment for late onset right ventricular failure in a patient supported with a left ventricular assist device.
Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Recovery of Function; Simendan; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right | 2020 |
[The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction].
Topics: Coronary Artery Bypass; Coronary Artery Disease; Humans; Hydrazones; Postoperative Complications; Prospective Studies; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Surgery: Neutral results for levosimendan in cardiac surgery.
Topics: Cardiac Surgical Procedures; Humans; Hydrazones; Simendan; Ventricular Dysfunction, Left | 2017 |
Evaluation of ventriculo-arterial coupling in ST elevation myocardial infarction with left ventricular dysfunction treated with levosimendan.
Topics: Aged; Aorta, Thoracic; Cardiotonic Agents; Echocardiography, Doppler; Elasticity; Female; Follow-Up Studies; Heart Ventricles; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Percutaneous Coronary Intervention; Prognosis; Retrospective Studies; Simendan; ST Elevation Myocardial Infarction; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
Peripheral venoarterial extracorporeal life support despite impending left ventricular thrombosis: a bridge to resolution.
Topics: Advanced Cardiac Life Support; Anticoagulants; Biopsy; Enoximone; Extracorporeal Circulation; Heparin; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Shock, Cardiogenic; Simendan; Vasodilator Agents; Venous Thrombosis; Ventricular Dysfunction, Left | 2013 |
Enteroviral myocarditis requiring extracorporeal membranous oxygenation in a 2 week old girl.
Topics: Cardiopulmonary Resuscitation; Cardiotonic Agents; Echocardiography; Enterovirus B, Human; Enterovirus Infections; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant, Newborn; Myocarditis; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2013 |
Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
Topics: Animals; Calcium Signaling; Cardiotonic Agents; Diastole; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Heart Failure; Hydrazones; Hypertrophy, Left Ventricular; Mice; Mice, Knockout; Myocytes, Cardiac; Pyridazines; Recovery of Function; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Stroke Volume; Systole; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2013 |
Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure.
Topics: Animals; Arterio-Arterial Fistula; Calcium Signaling; Cardiotonic Agents; Heart Failure; Hydrazones; Male; Myocardial Contraction; Myocytes, Cardiac; Myofibrils; Pyridazines; Rats; Rats, Sprague-Dawley; Sarcomeres; Simendan; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Early levosimendan administration is associated with decreased mortality after cardiac surgery.
Topics: Aged; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Artery Bypass; Female; Heart Valve Prosthesis Implantation; Hospital Mortality; Humans; Hydrazones; Intensive Care Units; Logistic Models; Male; Middle Aged; Odds Ratio; Postoperative Complications; Proportional Hazards Models; Pyridazines; Renal Insufficiency; Renal Replacement Therapy; Retrospective Studies; Simendan; Stroke Volume; Survival Rate; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction.
Topics: Adult; Aged; Combined Modality Therapy; Female; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Male; Middle Aged; Mitral Valve Insufficiency; Pyridazines; Severity of Illness Index; Simendan; Ultrasonography; Vasodilator Agents; Ventricular Dysfunction, Left | 2016 |
Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Drug Therapy, Combination; Hydrazones; Milrinone; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardial Stunning; Pyridazines; Recovery of Function; Simendan; Sus scrofa; Systole; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2016 |
Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery - a retrospective analysis.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass; Female; Humans; Hydrazones; Kidney; Male; Middle Aged; Postoperative Complications; Pyridazines; Retrospective Studies; Risk Factors; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.
Topics: Aged; Cardiac Output; Cardiotonic Agents; Combined Modality Therapy; Female; Hemodynamics; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Norepinephrine; Prospective Studies; Pyridazines; Shock, Cardiogenic; Simendan; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2008 |
Levosimendan: from basic science to clinical practice.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Kidney; Myocardial Contraction; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Quality of Life; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right | 2009 |
Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation.
Topics: Adult; Aged; Cardiotonic Agents; Drug Therapy, Combination; Echocardiography; Echocardiography, Transesophageal; Female; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2009 |
Timing of levosimendan in cardiac surgery.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Drug Administration Schedule; Female; Hemodynamics; Humans; Hydrazones; Intraoperative Care; Male; Middle Aged; Myocardial Contraction; Patient Selection; Postoperative Care; Pyridazines; Retrospective Studies; Simendan; Time Factors; Ventricular Dysfunction, Left | 2009 |
Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
Topics: Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Case-Control Studies; Drug Administration Schedule; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Phosphodiesterase Inhibitors; Preanesthetic Medication; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2009 |
Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pilot Projects; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Pulmonary Wedge Pressure; Pyridazines; Respiration; Respiration, Artificial; Simendan; Ventilator Weaning; Ventricular Dysfunction, Left | 2011 |
Combined exogenous and endogenous catecholamine release associated with Tako-Tsubo like syndrome in a patient with atrio-ventricular block undergoing pace-maker implantation.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Atrioventricular Block; Catecholamines; Diuretics; Echocardiography; Female; Humans; Hydrazones; Metaproterenol; Pacemaker, Artificial; Pyridazines; Simendan; Systole; Takotsubo Cardiomyopathy; Ventricular Dysfunction, Left | 2011 |
Levosimendan restores the positive force-frequency relation in heart failure.
Topics: Analysis of Variance; Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Disease Models, Animal; Dogs; Excitation Contraction Coupling; Heart Failure; Heart Rate; Hydrazones; Male; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume; Tachycardia; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2011 |
Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Diastole; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Italy; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Systole; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |
Positive inotropy for acute heart failure complicating myocardial infarction.
Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Evaluation; Heart Failure; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Diastole; Dobutamine; Dopamine; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Greece; Heart Failure; Heart Ventricles; Hematocrit; Hemoglobins; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Potassium; Pyridazines; Severity of Illness Index; Simendan; Stimulation, Chemical; Survival Analysis; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases.
Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Fibrillation; Calcium Channel Blockers; Cardiotonic Agents; Electrocardiography; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Middle Aged; Myocardial Infarction; Myocardial Stunning; Pericarditis; Pyridazines; Respiration, Artificial; Shock, Cardiogenic; Simendan; Ventricular Dysfunction, Left | 2005 |
Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction.
Topics: Aged; Aortic Valve Stenosis; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2006 |
Successful administration of levosimendan in a patient with low-gradient low-output aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Male; Perioperative Care; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Severe stunned myocardium after lightning strike.
Topics: Adult; Cardiotonic Agents; Causality; Critical Care; Disease Progression; Echocardiography; Electrocardiography; Epilepsy, Tonic-Clonic; Exercise Test; Female; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Lightning Injuries; Monitoring, Physiologic; Myocardial Stunning; Pyridazines; Radiopharmaceuticals; Recovery of Function; Severity of Illness Index; Shock, Cardiogenic; Simendan; Technetium Tc 99m Sestamibi; Thallium; Ventricular Dysfunction, Left | 2007 |
Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
Topics: Cardiac Output, Low; Cardiotonic Agents; Echocardiography; Follow-Up Studies; Gestational Age; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Infant, Premature, Diseases; Intensive Care Units, Pediatric; Male; Myocardial Stunning; Postoperative Complications; Pyridazines; Simendan; Time Factors; Transposition of Great Vessels; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Peripartum cardiomyopathy: a new successful setting for levosimendan.
Topics: Adult; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Postpartum Period; Pregnancy; Pyridazines; Risk Assessment; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
Topics: Adrenergic beta-Agonists; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Humans; Hydrazones; Milrinone; Myocardial Contraction; Perioperative Care; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
Letter by Guarracino et al regarding article, "Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships".
Topics: Heart Rate; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2007 |
Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anti-Arrhythmia Agents; Blood Pressure; Cardiac Output; Female; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Vascular Resistance; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Levosimendan and ventriculo-arterial coupling.
Topics: Cardiac Output; Cardiotonic Agents; Doppler Effect; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Vascular Resistance; Ventricular Dysfunction, Left | 2008 |
Rescue peri-operative management of the patient with giant electrical storm and severe left ventricular dysfunction: support by levosimendan and intraaortic balloon counterpulsation.
Topics: Aortic Valve Stenosis; Cardiac Pacing, Artificial; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Echocardiography; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Middle Aged; Perioperative Care; Pyridazines; Simendan; Tachycardia, Ventricular; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |